# Case Report: Rapid response to gemtuzumab-ozogamicin in a pediatric patient with refractory systemic mastocytosis with AML1::ETO+ acute myeloid leukemia

## TL;DR

A 6-year-old child with a rare and resistant form of leukemia showed quick improvement after treatment with gemtuzumab-ozogamicin.

## Contribution

This case report highlights the potential of gemtuzumab-ozogamicin as a salvage therapy for refractory systemic mastocytosis with AML1::ETO+ AML.

## Key findings

- Gemtuzumab-ozogamicin induced rapid remission in a pediatric patient with refractory systemic mastocytosis and AML.
- Standard salvage treatments failed, but gemtuzumab-ozogamicin was effective in this rare case.

## Abstract

This article describes a 6-year-old patient diagnosed with “systemic mastocytosis with AML1::ETO+ AML”, he experience refractory disease during the course of treatment and salvage treatment was ineffective. The patient was administered gemtuzumab-ozogamicin therapy, resulting in rapid remission.